… towards a treatment of CFS?
Scientists at University of Utah in Salt Lake City, Utah, and Emory University at Decatur, Georgia now report that several HIV drugs inhibit the replication of XMRV in cell cultures.
Here is the original report:
Raltegravir Is a Potent Inhibitor of XMRV, a Virus Implicated in Prostate Cancer and Chronic Fatigue Syndrome
Ila R. Singh, John E. Gorzynski, Daria Drobysheva, Leda Bassit, Raymond F. Schinazi
PLoS ONE 5(4): e9948. doi:10.1371/journal.pone.0009948
They write the following:
Forty-five compounds, including twenty-eight drugs approved for use in humans, were evaluated against XMRV replication in vitro. We found that the retroviral integrase inhibitor, raltegravir, was potent and selective against XMRV at submicromolar concentrations, in MCF-7 and LNCaP cells, a breast cancer and prostate cancer cell line, respectively. Another integrase inhibitor, L-000870812, and two nucleoside reverse transcriptase inhibitors, zidovudine (ZDV), and tenofovir disoproxil fumarate (TDF) also inhibited XMRV replication. When combined, these drugs displayed mostly synergistic effects against this virus, suggesting that combination therapy may delay or prevent the selection of resistant viruses.
You can also read more at:
Powerful HIV drugs inhibit retrovirus linked to prostate cancer, chronic fatigue syndrome
Anti-HIV drugs inhibit emerging virus linked to prostate cancer and chronic fatigue syndrome